D116 Unit 8 Study Guide

D116 Unit 8 Study Guide

Student Name

Western Governors University 

D116 Advanced Pharmacology for the Advanced Practice Nurse

Prof. Name

Date

Unit 8 Study Guide

---

What are adverse reactions and interactions with muscarinic agonists?

Muscarinic agonists are drugs that activate muscarinic receptors in the parasympathetic nervous system, mimicking the effects of acetylcholine. Bethanechol is a frequently prescribed muscarinic agonist, commonly utilized to treat urinary retention and disorders affecting gastrointestinal motility. However, because these agents stimulate parasympathetic activity broadly, they can cause multiple adverse effects.

From a cardiovascular perspective, muscarinic agonists may induce hypotension due to peripheral vasodilation and slow the heart rate (bradycardia) through increased vagal nerve stimulation. The gastrointestinal system is particularly sensitive, with typical adverse effects including excessive salivation, heightened gastric acid secretion, abdominal cramps, nausea, and diarrhea. These symptoms result from enhanced smooth muscle contraction and increased glandular secretions.

Respiratory side effects are particularly important to consider, especially in patients with reactive airway diseases such as asthma or chronic obstructive pulmonary disease (COPD). Muscarinic agonists can cause bronchoconstriction and promote increased mucus secretion, which may exacerbate these respiratory conditions. Given these risks, caution is advised when prescribing muscarinic agonists to individuals with underlying cardiovascular, gastrointestinal, or pulmonary disorders.

---

If patients continue to be re-infected with UTIs, what medication prophylaxis should be given? Differentiate between reinfection and relapse.

Recurrent urinary tract infections (UTIs) present a frequent clinical challenge, especially in women. Treatment strategies vary depending on whether the infection represents a reinfection or a relapse, as these two have distinct causes and management implications.

Reinfection refers to a new infection caused by a different bacterial strain after the previous infection has been completely treated. Factors such as sexual activity, spermicide use, or alterations in vaginal flora often contribute to reinfections. If reinfections are rare (one to two episodes annually), each episode is managed with a standard short course of antibiotics. For patients experiencing frequent reinfections, prophylactic antibiotic therapy, such as low-dose nitrofurantoin, may be prescribed to reduce recurrence.

Relapse, on the other hand, involves the return of infection symptoms shortly after completing antibiotic therapy, typically caused by the same bacterial organism that was never fully eradicated. This pattern suggests underlying problems such as urinary tract obstruction, kidney stones, or chronic bacterial prostatitis in men. Relapses require thorough diagnostic evaluation and usually necessitate prolonged or alternative antibiotic treatment.

Nitrofurantoin is favored as a first-line agent for uncomplicated cystitis due to its effective antibacterial action and minimal disturbance to the gut microbiome.

---

Comparison of Reinfection and Relapse in UTIs

Aspect	Reinfection	Relapse
Underlying Cause	New bacterial exposure, often linked to sexual activity or contraceptive use	Persistence of the original bacterial strain
Timing of Recurrence	Occurs after complete symptom resolution	Occurs shortly after finishing antibiotic therapy
Treatment Strategy	Treat each episode individually; consider prophylaxis if frequent	Investigate structural or chronic causes; longer therapy may be required
Frequency	Usually infrequent (1–2 episodes per year)	Rapid recurrence following treatment

---

Discuss the treatment for a pediatric patient with a UTI.

Managing UTIs in pediatric patients requires consideration of age, safety, and effective antimicrobial coverage. For children aged six to twelve years, methenamine hippurate can be used for prophylaxis in recurrent UTIs, especially when no renal abnormalities are present. Methenamine acts by releasing formaldehyde in acidic urine, which inhibits bacterial growth.

In neonates and infants younger than six months, the standard approach is empirical treatment with intravenous ampicillin combined with gentamicin. This combination provides broad-spectrum coverage against common neonatal pathogens while maintaining safety. Prompt diagnosis and initiation of therapy are crucial in this age group to prevent kidney damage and long-term complications.

---

Discuss the specific treatment for patients with enterococcal endocarditis.

Treating enterococcal endocarditis is complex due to the inherent resistance of Enterococcus species to many antibiotics, making monotherapy typically inadequate. The recommended treatment involves combination therapy to achieve a synergistic bactericidal effect.

A penicillin-class antibiotic such as ampicillin or penicillin G is combined with an aminoglycoside like gentamicin. This regimen improves bacterial eradication, particularly in infections involving heart valves. Treatment durations are prolonged, reflecting the seriousness and difficulty in clearing these infections.

---

How is gonorrhea treated?

Gonorrhea, caused by Neisseria gonorrhoeae, requires effective antimicrobial treatment due to increasing antibiotic resistance. Current guidelines endorse third-generation cephalosporins as the primary treatment option because of their potent activity against resistant strains.

Administering cephalosporins promptly helps prevent complications including pelvic inflammatory disease, infertility, and disseminated infections. Strict adherence to these recommendations is vital to prevent the development of further antimicrobial resistance.

---

What is epinephrine used for? What is the mechanism of action?

Epinephrine is a non-selective adrenergic agonist that activates alpha (α₁, α₂) and beta (β₁, β₂) adrenergic receptors but has no action on dopamine receptors. It is predominantly used in emergency situations such as anaphylaxis, cardiac arrest, and severe asthma attacks.

Its mechanism involves α₁ receptor-mediated vasoconstriction, which increases blood pressure and reduces swelling in mucous membranes. The β₂ receptor stimulation causes bronchodilation, facilitating easier airflow during respiratory distress. Additionally, β₁ receptor activation enhances heart rate and contractility, boosting cardiac output. These combined actions make epinephrine a critical, lifesaving drug in acute allergic and cardiac emergencies.

---

Which allergy medication is best for children? What are the side effects?

Antihistamines are commonly used in children to alleviate allergic symptoms. Among them, second-generation antihistamines are preferred because they cause less sedation compared to first-generation agents.

Side effects in pediatric patients typically mirror those seen in adults and can include drowsiness, dizziness, impaired coordination, fatigue, gastrointestinal discomfort, and confusion. It is important to note that promethazine is contraindicated in children younger than two years due to the risk of fatal respiratory depression and should not be used in this population.

---

What should the healthcare provider look for when discontinuing gout medications?

When stopping gout treatments, healthcare providers must vigilantly observe for early signs of adverse reactions to prevent serious complications.

For colchicine, therapy should be halted immediately if patients experience severe gastrointestinal symptoms such as diarrhea, vomiting, or abdominal pain, as these could indicate toxicity.

For allopurinol, discontinuation is required at the first sign of rash, fever, or systemic symptoms that may suggest a hypersensitivity reaction. Early cessation can prevent progression to life-threatening conditions like severe skin reactions or systemic involvement.

---

References

American Academy of Pediatrics Committee on Infectious Diseases. (2019). Red Book: 2018–2021 report of the Committee on Infectious Diseases. American Academy of Pediatrics.

Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2018). Goodman & Gilman’s the pharmacological basis of therapeutics (13th ed.). McGraw-Hill Education.

Katzung, B. G., Masters, S. B., & Trevor, A. J. (2022). Basic and clinical pharmacology (15th ed.). McGraw-Hill Education.

Mandell, G. L., Bennett, J. E., & Dolin, R. (2020). Principles and practice of infectious diseases (9th ed.). Elsevier.